Clinical trials: Clinical Malaria
Malaria
Antioxidant Micronutrients in Malaria
In the last decade, the prevalence of malaria has been escalating at an alarming rate, especially in Africa. An estimated 300 to 500 million cases each year cause 1.5 to 2.7 million deaths, more than 90% occur in children under 5…
- Trial name
- AMM (NCT01152931)
- Testing
- Amodiaquine + Artesunate, Lumefantrine + Artemether, Artesunate + vitamin A
- Where
- 2 sites in Nigeria
- Volunteers
- 10 people
- Sponsor
- University of Lagos, Nigeria
Plasmodium Falciparum Malaria
Assessing the Safety, Immunogenicity and Ex-vivo Efficacy of Two Candidate Malaria Transmission Blocking Vaccines, Pfs25-IMX313 and Pfs45/48 Administered Alone and in Combination, in Matrix-M Adjuvant
Assessing the safety, immunogenicity and ex-vivo efficacy of two transmission blocking vaccines (Pfs25-IMX313 in Matrix M and Pfs48/45 in Matrix M alone and co-administered) in Burkina Faso, in 18-45 years, 12-17 years and 05-11…
- Trial name
- NCT06549257
- Testing
- Pfs25-IMX313, Pfs48/45
- Where
- Burkina Faso
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Cerebral Malaria
Mannitol as Adjunct Therapy for Childhood Cerebral Malaria
Cerebral malaria is a life-threatening complication of Plasmodium falciparum infection in African children and nonimmune travellers despite availability of quinine, the current drug of choice.
- Trial name
- NCT00113854
- Testing
- Mannitol
- Where
- Uganda
- Volunteers
- 156 people
- Sponsor
- Makerere University
Uncomplicated Falciparum Malaria, Vivax Malaria
A Comparative Study of Artekin With Standard Malarial Treatment Regimes in Afghanistan
Malaria is a major public health problem in many provinces of Afghanistan the failure rate of chloroquine (CQ) and amodiaquine (AQ) treated Plasmodium falciparum(Pf) malaria has risen to more than 60% overall and as high as 90%…
- Trial name
- NCT00682578
- Testing
- Dihydroartemisinin + Piperaquine (Artekin), artesunate-sulphadoxin/pyrimethamine, chloroquine
- Where
- 4 sites in Afghanistan
- Volunteers
- 1,086 people
- Sponsor
- University of Oxford
Malaria
Paracetamol Effect on Oxidative Stress and Renal Function in Severe Malaria
Blackwater fever, characterized by intravascular haemolysis and hemoglobinuria, is an important cause of renal impairment and mortality in severe malaria caused by Plasmodium falciparum.
- Trial name
- NCT01641289
- Testing
- Paracetamol, No Paracetamol
- Where
- 2 sites in Bangladesh
- Volunteers
- 62 people
- Sponsor
- University of Oxford
Malaria, Plasmodium Vivax
Phase Ia Study of ChAd63/MVA PvDBP
This is an open label phase Ia study, to assess the safety of two novel malaria vaccines, ChAd63 PvDBP, with or without MVA PvDBP.
- Trial name
- NCT01816113
- Testing
- ChAd63 PvDBP 5 x 10^9, ChAd63 PvDBP 5 x 10^10, MVA PvDBP 1 x 10^8
- Where
- United Kingdom
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Malaria
Clinical Performance Evaluation of Fyodor Urine Malaria Test (UMT)
The purpose of this study is to evaluate the clinical performance of the one-step Fyodor Urine Malaria Test (UMT), to determine its accuracy (sensitivity and specificity) for the diagnosis of Plasmodium falciparum malaria in…
- Trial name
- NCT01921413
- Testing
- Urine Malaria Test
- Where
- Nigeria
- Volunteers
- 1,893 people, healthy volunteers welcome
- Sponsor
- Fyodor Biotechnologies Inc
Plasmodium Falciparum Malaria
Phase I Pediatric FMP2.1/AS02A Trial in Mali
The purpose of this study is to test the safety and dosages of a malaria vaccine in 100 children, 1-6 years old, in Bandiagara, Mali.
- Trial name
- NCT00358332
- Testing
- FMP2.1/AS02A, Rabies vaccine (RabAvert)
- Where
- Mali
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- U.S. Army Medical Research and Development Command
Malaria
Prevention of P. Vivax Malaria During Pregnancy in Bolivia
The purpose of this study is to determine which, between weekly prophylaxis or malaria attack treatment, both by chloroquine, is the most appropriate way to protect women and foetus from P.
- Trial name
- NCT00290420
- Testing
- Chloroquine profilaxis
- Volunteers
- healthy volunteers welcome
- Sponsor
- Institut de Recherche pour le Developpement
Malaria
Introduction of Eurartesim® in Burkina Faso, Mozambique, Ghana and Tanzania
WHO recommends the use of artemisinin-based combination therapies (ACTs) in the treatment of uncomplicated malaria to stem falciparum malaria drug resistance.
- Trial name
- NCT02199951
- Testing
- Dihydroartemisinin and piperaquine
- Where
- 7 sites in Burkina Faso, Ghana and 2 more
- Volunteers
- 10,000 people
- Sponsor
- INDEPTH Network
Uncomplicated Plasmodium Falciparum
Momordica Charantia and Dihydroartemisinin-piperaquined-primaquine for Uncomplicated Plasmodium Falciparum Malaria Patients in Southwest Sumba Regency
Currently, the first-line combination of artemisinin, piperaquine and prima-quine is quite effective in controlling malaria, however, the threat of spread of drug-resistant parasites has been reported.
- Trial name
- MCHUPF (NCT05829187)
- Testing
- Dihydroartemisinin, Piperaquine, Primaquine
- Where
- Indonesia
- Volunteers
- 36 people
- Sponsor
- Syamsudin Abdillah,Ph.D, Pharm D
Pneumonia, Bacterial, Viral Infection
Diagnostic and Prognostic Biomarkers for Childhood Bacterial Pneumonia
Clinical pneumonia is a leading cause of pediatric hospitalization. The etiology is generally bacterial or viral. Prompt and optimal treatment of pneumonia is critical to reduce mortality.
- Conditions
- Pneumonia, Bacterial, Viral Infection, Clinical Pneumonia, Plasmodium Falciparum Malaria
- Trial name
- NCT03996967
- Where
- 3 sites in United States, Netherlands and 1 more
- Volunteers
- 837 people
- Sponsor
- Boston University
Plasmodium Vivax Infection
Clinical Study to Assess Minimum Mosquito Bites for P. Vivax Infection in Thai Adults
This study is a human challenge study to assess the minimum infective mosquito bite dose in a controlled human malaria Infection (via P. vivax sporozites) in healthy volunteers. The results will inform the development of a P.
- Trial name
- MIST4 (NCT07257965)
- Testing
- Mosquito bite (1 or 2 or 3)
- Where
- Thailand
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Malaria, Diagnoses Disease
Clinical Validation of Novel Malaria Diagnostic Tools for POC Point-of-Care Testing
The aim of this study is to perform a performance evaluation of novel diagnostic tools for detecting malaria in malaria-endemic countries.
- Conditions
- Malaria, Diagnoses Disease, RDT
- Trial name
- NCT06225700
- Where
- Rwanda
- Volunteers
- 509 people
- Sponsor
- Foundation for Innovative New Diagnostics, Switzerland
Prevention of Malaria Transmission and Clinical Malaria
Pfs230D1 + R21 in Matrix-M1 in African School Children and Adults
This is a Phase 2, randomized, double-blind, controlled study designed to evaluate the safety, tolerability, immunogenicity, vaccine efficacy, and functional activity of Pfs230D1-CRM197 conjugate vaccine with R21 nanoparticle…
- Trial name
- NCT07147400
- Testing
- 10µg of R21 with 50µg Matrix-M1, 6µg of Pfs230D1-CRM197 + 10µg of R21 with 50µg Matrix-M1 single vial coformulation, RABIVAX-S
- Where
- Mali
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- Serum Institute of India Pvt. Ltd.
Malaria
In Vivo Efficacy of Artemether-lumefantrine and Amodiaquine-artesunate in Mozambican Children (MEFI_III)
This is a classical in vivo clinical trial, following World Health organization's recommendations, ran as a multisite study within Mozambique trying to assess the efficacy and safety in 4 sites of the two oral ACTS…
- Trial name
- MEFI_III (NCT04370977)
- Testing
- Coartem™ (Artemether-lumefantrine combination), Winthrop™ (Amodiaquine-artesunate combination)
- Where
- 6 sites in Mozambique
- Volunteers
- 630 people
- Sponsor
- Centro de Investigacao em Saude de Manhica
Lung Cancer, Nonsmall Cell
Plasmodium Immunotherapy for Lung Cancer
The objective of this study is to evaluate the safety and the effectiveness of Plasmodium immunotherapy (blood-stage infection of Plasmodium vivax) for advanced non-small cell lung cancer.The treatment will last 3-6 months from…
- Trial name
- NCT02786589
- Testing
- Blood-stage infection of P. vivax
- Where
- China
- Volunteers
- 30 people
- Sponsor
- State Key Laboratory of Respiratory Disease
Malaria, Vivax
Safety, Immunogenicity and Efficacy of the Blood-stage Plasmodium Vivax Malaria Vaccine Candidate PvDBPII in Matrix M1
This is an Open label, first-in-human, Phase I/IIa, blood-stage P. vivax malaria vaccine trial to assess the safety, immunogenicity and efficacy of the blood-stage Plasmodium vivax malaria vaccine candidate PvDBPII in Matrix M1…
- Trial name
- NCT04201431
- Testing
- PvDBPII/Matrix-M1
- Where
- United Kingdom
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Healthy, Malaria
A Phase I Clinical Trial Immunizing Healthy Adults With the NMRC-M3V-Ad-PfCA Vaccine to Generate Biologic Reagents
This is an open label Phase 1 study of the Ad-PfCA vaccine designed to 1) provide reagents for the development and refinement of cell-mediated immunoassays for measuring the human immune response to candidate malaria vaccines…
- Trial name
- AdBa (NCT01843491)
- Testing
- Ad-PfCA
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- U.S. Army Medical Research and Development Command
Malaria, Falciparum
A Phase Ia Clinical Trial to Assess the Safety and Immunogenicity of the Blood-stage Malaria Candidate Vaccines RH5.1 in Matrix-M and R78C in Matrix-M in Healthy UK Adults
This is an open-label, single-centre Phase I P. falciparum blood-stage vaccine trial to assess the safety and immunogenicity and efficacy of the candidate malaria vaccines R78C and RH5.1 formulated in adjuvant Matrix-M
- Trial name
- NCT05385471
- Testing
- Matrix M with R78C and/or RH5.1
- Where
- United Kingdom
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- University of Oxford